What’s the current market cap for Elekta AB stock?

Elekta AB (EKTA B) has a market cap of Skr20bn as of June 17, 2026.

What is the P/E ratio for Elekta AB stock?

The price to earnings (P/E) ratio for Elekta AB (EKTA B) stock is 0 as of June 17, 2026.

Does Elekta AB stock pay dividends?

Yes, the Elekta AB (EKTA B) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is Skr2.4 and the yield is 4.63%. Elekta AB has a payout ratio of 0% on a trailing twelve-month basis.

When is the next Elekta AB dividend payment date?

The next Elekta AB (EKTA B) dividend payment date is unconfirmed.

What is the beta indicator for Elekta AB?

Elekta AB (EKTA B) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Elekta AB stock | SkrEKTA B Share Price

07:00

09:05

11:15

13:20

15:25

About Elekta AB

Elekta AB is a Swedish company specializing in the development and production of medical technologies used in radiotherapy and radiosurgery for treating cancer and brain disorders. Founded in 1972 and headquartered in Stockholm, Sweden, Elekta offers a range of products including linear accelerators, brachytherapy solutions, and software for treatment planning and digital health records management. The company is recognized for its emphasis on precision and efficiency in treatment delivery. Elekta operates globally, serving hospitals and cancer care centers across multiple continents, leveraging technological innovations to improve patient outcomes and workflow efficiency in healthcare facilities. Its strategic focus includes the continuous advancement of image-guided radiation therapy technologies.

Ticker

Skr EKTA B

Sector

Health

Primary listing

XSTO

Employees

4,353

Headquarters

Stockholm, Sweden

Website

www.elekta.com

Elekta AB Metrics

BasicAdvanced

kr 20bn

-kr 1.36

0.96

kr 2.40

4.63%

Bulls say / Bears say

In January 2026, the US FDA granted 510(k) clearance for the Elekta Evo linear accelerator, opening the US market to the new platform and laying the foundation for increased sales in North America. (Omni)

The January 30, 2026 strategic update outlined a workforce reduction of 450 employees, projected to deliver more than SEK 500 million in annual cost savings and support margin improvement. (Elekta)

In Q4 FY2025/26, Elekta achieved an adjusted EBITDA margin of 25.3%, up from 22.6% a year earlier, reflecting operational efficiency gains from its cost discipline. (Elekta Q4 report)

Q4 order intake fell 15% in constant currency to SEK 4.57 billion, missing consensus by SEK 1.26 billion, indicating weakening demand momentum. (Investing.com)

Full-year FY2025/26 net sales declined 7% to SEK 16.72 billion from SEK 18.02 billion in FY2024/25, reflecting persistent top-line contraction. (S&P Capital IQ)

Elekta’s US market share has slipped from 23% to 21% over the past five years, suggesting intensifying competitive pressures in a key region. (Placera.se)

Data summarised monthly by Lightyear AI. Last updated on 14 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Skr EKTA B

Skr

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

The January 30, 2026 strategic update outlined a workforce reduction of 450 employees, projected to deliver more than SEK 500 million in annual cost savings and support margin improvement. (Elekta)

In Q4 FY2025/26, Elekta achieved an adjusted EBITDA margin of 25.3%, up from 22.6% a year earlier, reflecting operational efficiency gains from its cost discipline. (Elekta Q4 report)

Q4 order intake fell 15% in constant currency to SEK 4.57 billion, missing consensus by SEK 1.26 billion, indicating weakening demand momentum. (Investing.com)

Full-year FY2025/26 net sales declined 7% to SEK 16.72 billion from SEK 18.02 billion in FY2024/25, reflecting persistent top-line contraction. (S&P Capital IQ)

Elekta’s US market share has slipped from 23% to 21% over the past five years, suggesting intensifying competitive pressures in a key region. (Placera.se)

Data summarised monthly by Lightyear AI. Last updated on 14 Jun 2026.

About Elekta AB

Ticker

Primary listing

Employees

Headquarters

Elekta AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr EKTA B

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Elekta AB/Skr EKTA B

About Elekta AB

Ticker

Primary listing

Employees

Headquarters

Elekta AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr EKTA B

Upcoming events

No upcoming events

What’s the current market cap for Elekta AB stock?

What is the P/E ratio for Elekta AB stock?

Does Elekta AB stock pay dividends?

When is the next Elekta AB dividend payment date?

What is the beta indicator for Elekta AB?

Bulls say / Bears say